HC Wainwright Cuts Tyra Biosciences (NASDAQ:TYRA) Price Target to $30.00

Tyra Biosciences (NASDAQ:TYRA) had its target price lowered by HC Wainwright from $32.00 to $30.00 in a research note released on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Tyra Biosciences’ Q4 2024 earnings at ($0.52) EPS, FY2024 earnings at ($1.59) EPS, Q1 2025 earnings at ($0.53) EPS, Q2 2025 earnings at ($0.54) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.56) EPS and FY2025 earnings at ($2.17) EPS.

Other equities analysts also recently issued research reports about the stock. Wedbush reiterated an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a report on Friday, October 25th. Oppenheimer lifted their price target on shares of Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research report on Thursday, September 19th. Bank of America raised Tyra Biosciences from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $22.00 to $31.00 in a research note on Friday, October 18th. Finally, Piper Sandler began coverage on Tyra Biosciences in a research note on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price objective for the company. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $31.00.

Tyra Biosciences Trading Up 3.8 %

NASDAQ TYRA opened at $16.34 on Monday. The stock has a market capitalization of $826.80 million, a price-to-earnings ratio of -10.15 and a beta of 1.08. The business’s 50 day moving average is $21.51 and its two-hundred day moving average is $19.98. Tyra Biosciences has a 12-month low of $10.60 and a 12-month high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). Equities analysts forecast that Tyra Biosciences will post -1.56 earnings per share for the current fiscal year.

Insider Activity

In other Tyra Biosciences news, CEO Todd Harris sold 10,092 shares of the company’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $24.13, for a total value of $243,519.96. Following the transaction, the chief executive officer now directly owns 1,479,528 shares in the company, valued at approximately $35,701,010.64. This represents a 0.68 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Nina S. Kjellson sold 11,078 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $16.17, for a total transaction of $179,131.26. Following the transaction, the director now directly owns 472,207 shares in the company, valued at $7,635,587.19. The trade was a 2.29 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 101,050 shares of company stock worth $2,235,492 over the last ninety days. 15.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Tyra Biosciences

Several institutional investors have recently added to or reduced their stakes in TYRA. HighVista Strategies LLC purchased a new stake in Tyra Biosciences in the 2nd quarter valued at about $257,000. Valence8 US LP acquired a new position in Tyra Biosciences during the third quarter worth approximately $310,000. SG Americas Securities LLC purchased a new position in Tyra Biosciences during the third quarter worth approximately $311,000. The Manufacturers Life Insurance Company acquired a new position in shares of Tyra Biosciences in the 3rd quarter valued at $333,000. Finally, Rhumbline Advisers grew its stake in shares of Tyra Biosciences by 12.3% during the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock valued at $377,000 after buying an additional 2,574 shares during the period. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.